Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference [Yahoo! Finance]
Biogen Inc. (BIIB)
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
biogen.com/en_us/investors.html
Company Research
Source: Yahoo! Finance
the team from about 45 to 100+ employees and launching three Phase 3 studies over the past year. Biogen has positioned antibody-mediated rejection (AMR) as the lead indication after a Phase 2 showing 80% histologic reversal; a 120-patient global Phase 3 with a six-month primary endpoint is enrolling, with a topline readout expected next year and Breakthrough/Orphan designations in place. Felzartamab is also in Phase 3 for IgA nephropathy and primary membranous nephropathy and in Phase 2 for microvascular inflammation (MVI), while Biogen pursues a subcutaneous formulation and next-generation anti-CD38 to support commercialization concentrated at major transplant and glomerular centers. Interested in Biogen Inc.? Here are five stocks we like better. 3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 Biogen (NASDAQ:BIIB) outlined its growing “West Coast Hub” and development plans for felzartamab, an anti-CD38 antibody being studied across multiple kidney-related immuno
Show less
Read more
Impact Snapshot
Event Time:
BIIB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIIB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
News
- Biogen Stock: Is BIIB Outperforming the Healthcare Sector? [Yahoo! Finance]Yahoo! Finance
- Here's Why Biogen Inc. (BIIB) is a Strong Value Stock [Yahoo! Finance]Yahoo! Finance
- Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy [Yahoo! Finance]Yahoo! Finance
- Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene TherapyGlobeNewswire
- Aduhelm (Biogen, Eisai) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]Yahoo! Finance
BIIB
Earnings
- 2/9/26 - Beat
BIIB
Sec Filings
- 3/11/26 - Form 8-K
- 2/17/26 - Form 4
- 2/17/26 - Form 4
- BIIB's page on the SEC website